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1.1 Introduction
In most randomized trials, individuals are randomized to study conditions
and then followed to compare their outcomes. In a cluster randomized trial
(CRT), also called a group randomized trial, preexisting groups of individuals
such as clinics, schools or communities are randomized to conditions, with all
individuals in the same group receiving the same treatment. After a follow-up
period, outcomes are typically measured at the individual level. Examples of
interventions that have been studied using a cluster randomized design include
an intervention to improve the patient care experience for cancer patients
that randomized nurses [63], an educational intervention to promote serologic
testing for hepatitis B that randomized churches [5] and a cervical cancer
screening program in rural India that randomized villages [54].
When individuals are randomized to conditions and do not interact with
each other, their outcomes are generally regarded as independent. When pre-
existing groups are randomized, the outcomes of individuals in the same
group cannot be considered independent. Rather, members of the same group
share some commonalities — they may be patients with the same health care
provider, children attending the same school or residents of the same village
— and also may interact during the treatment period, which will make the
outcomes of individuals in the same group more similar than the outcomes of
individuals from different groups. As explained in Section 1.3.1.1, this corre-
lation of outcomes within groups makes cluster randomized trials less statis-
tically efficient (that is, the intervention effect estimates have larger standard
errors) than individually randomized trials in which clustering does not oc-
cur. As a result, cluster randomized trials require larger overall numbers of
individuals to achieve the same level of statistical power. They also require
the use of data analysis methods that account for clustering.
If cluster randomized trials are less efficient, why use them? Various con-
siderations may motivate the selection of a cluster randomized design. The
intervention may naturally be implemented at the group level, e.g., group
therapy or education sessions or a clinic-wide change in procedures. It may be
less costly or logistically easier to implement the intervention at the cluster
level. Cluster randomization can also prevent “contamination,” that is, expo-
sure of the control group to the intervention. Contamination tends to reduce
differences in outcomes between conditions, making it more difficult to detect
a treatment effect.
A key characteristic of cluster randomized trials is that they have multi-
level data structure, with individuals at the lower level and clusters at the
higher level. Thus design and analysis of cluster randomized trials are nat-
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urally handled using multilevel modeling. Multilevel models are extendable
to accommodate other modeling features such as covariates and additional
hierarchical structure such as repeated measures on individuals or additional
levels. In this chapter we emphasize the multilevel modeling approach to clus-
ter randomized trial design and analysis. For general treatments of multilevel
model analysis, see [26, 57].
This chapter is organized into three sections: randomization, analysis, and
sample size and power. R code to implement methods is provided. Due to
space constraints, we confine our attention to CRTs with two-level designs and
a continuous or dichotomous outcome. Resources for CRTs with time-to-event
or count outcomes or with more complex design elements such as additional
levels, stepped wedge or crossover designs are provided in Section 1.5.
1.2 Randomization
Randomization helps to ensure balance across conditions on known and un-
known prognostic factors. Due to randomization, we expect that the only
systematic difference between two study arms will be that one received the
intervention and the other did not; hence a comparison of the two conditions
produces an unbiased estimate of the treatment effect.
Compared to an individually randomized trial, the number of randomized
units in a cluster randomized trial is often relatively small, and simple random-
ization without restrictions (i.e., a coin flip) can result in chance imbalance
between arms on important baseline covariates. For example, if 10 clinics are
randomized to two conditions purely by chance, we may end up with most of
the larger clinics in one arm and the smaller clinics in the other. Additionally,
the number of clusters allocated to each arm may end up unequal. We briefly
discuss several strategies for avoiding these problems, including matching and
stratification, constrained randomization and minimization. For a more thor-
ough discussion, see [23, 28].
1.2.1 Matching and stratification
In a matched or stratified design, clusters are sorted into groups or “strata”
based on one or more prognostic factors, then clusters within strata are ran-
domized to conditions [15, 23, 43]. A matched-pair design is the special case
of strata of size 2; clusters are paired and one cluster in each pair is assigned
to each condition. Randomization within strata defined by one or more char-
acteristics ensures balance between arms on these characteristics.
The Korean Health Study [5] provides an example of the use of stratified
randomization in a cluster randomized trial. This study evaluated a church-
based intervention to improve hepatitis B virus serological testing among Ko-
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rean Americans in Los Angeles. Fifty-two Korean churches were stratified by
size (small, medium, large) and location (Koreatown versus other) and ran-
domized to intervention or control conditions within the six strata. This en-
sured balance between the intervention and control arms on size and location.
Church location was considered potentially prognostic because of accultura-
tion differences among participants attending churches inside versus outside
Koreatown. Church size was considered prognostic because of the potential
for competing activities and resource differences at larger churches.
1.2.2 Constrained randomization
Stratification or matching become difficult when there are many matching or
stratification factors and a limited number of clusters. Constrained random-
ization, also called restricted randomization, is an alternative [23, 47]. Con-
strained randomization involves generating all possible allocations of clusters
to conditions, identifying the allocations that satisfy some predetermined bal-
ance criteria, then randomly selecting one allocation from the constrained set.
This ensures acceptable balance on the predetermined criteria.
Constrained randomization was used in the implementation study reported
by Maxwell et al. [38]. This study evaluated two strategies for implementing
an evidence-based intervention to promote colorectal cancer screening in Fil-
ipino American community organizations. Twenty-two community organiza-
tions were randomized to either a basic or enhanced implementation strategy.
Constrained randomization was used to ensure balance as well as to avoid
contamination across arms. The investigators enumerated all two-group equal
allocations of the 22 organizations that balanced the arms as to faith-based
versus non-faith-based organizations, organizations with prior experience with
the screening program versus organizations with no prior exposure, and zip
code-level mean income and education, and also kept three organizations that
were in close geographic proximity in the same arm (to prevent contamina-
tion), and randomly selected one of these allocations. The two groups were
then randomly assigned to the basic or enhanced implementation strategy
using a coin flip.
1.2.3 Minimization
Constrained randomization requires that all participating clusters be recruited
and have relevant covariate information available at the beginning of the study.
When clusters are recruited and randomized sequentially and/or there are
many factors to balance, an alternative is minimization [59]. In minimization,
the first few units (individuals in individually randomized trials, clusters in
cluster randomized trials) are randomly assigned to conditions and subsequent
units are randomized to the arm that will minimize an imbalance measure that
considers multiple covariates. Although minimization has not been widely used
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in cluster randomized trials [29], its ability to balance many covariates makes
it an attractive option.
Randomization in cluster randomized trials
Cluster randomized trials typically involve a relatively small number
of clusters, and as a result, simple unrestricted randomization can result
in chance imbalance between arms on important prognostic factors. Tech-
niques such as matching, stratification, constrained randomization and min-
imization can be useful for promoting balance across study arms.
1.3 Analysis
In this section, we discuss conducting the outcome analysis for cluster random-
ized trials. As discussed in the introduction, we focus on a multilevel modeling
approach. We begin with a multilevel model for two-level data with a contin-
uous outcome variable. This model introduces important concepts, including
the intraclass correlation coefficient and the design effect. We then discuss
estimation and inference for the intervention effect for continuous outcomes
and for dichotomous outcomes.
Throughout this section, we assume that we have balanced data, meaning a
two-arm trial with equal numbers of clusters in each condition and each cluster
having an equal number of members. This assumption simplifies the derivation
of key results. In practice, CRTs often have unequal numbers of clusters in
each condition and clusters with varying numbers of members. In general, this
does not alter the basic approach to estimation and inference using a general
or generalized linear mixed effects model. However, these factors can have an
impact on statistical power and sample size requirements. For this reason, we
defer discussion of these issues to Section 1.4.
1.3.1 Continuous outcomes
Assume that we have continuous, normally distributed outcomes on individu-
als who are nested within clusters. For example, we may have pain scores on
patients nested within hospital wards or depressive symptom scores on indi-
viduals nested within therapists. We set up a model for a single population
of clusters and study some properties of the model. Then we add a covari-
ate to encode cluster condition and discuss estimation and inference for the
intervention effect.
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1.3.1.1 Model
The basic model for a single population of clusters assumes that each cluster
has its own mean and individuals within the cluster have outcomes that vary
around that mean. The model for the outcome of individual i in cluster j,
denoted Yij , is
Yij = µj + ij , (1.1)
where µj is the mean for cluster j and ij is the error term indicating the
discrepancy between the individual’s observed outcome Yij and the cluster
mean outcome µj .
We further assume that our clusters are sampled from a population of
clusters that has an overall mean, with the cluster means varying around it.
The model for the mean of cluster j, µj , is
µj = γ0 + uj (1.2)
where γ0 denotes the population mean, assumed to be fixed, and uj is a
random effect representing the discrepancy between cluster j’s mean and the
population mean. Substituting equation (1.2) into equation (1.1) gives the
single equation model
Yij = γ0 + uj + ij . (1.3)
The random effects are assumed to be normal, with uj ∼ N(0, σ2u) and ij ∼
N(0, σ2 ), and to be independent of each other.
Model (1.3) is a simple model for two-level normally distributed data.
Inspection of the model reveals that the total variance of an observation Yij ,
not conditional on cluster, can be decomposed as the sum of two independent
variance components, one at the cluster level and the other at the individual
level, namely,
V ar(Yij) = σ
2
y = σ
2
u + σ
2
 . (1.4)
Note that σ2 is the conditional variance of observations given that they are
from the same cluster, and we expect that this variance will be lower than the
total variance, i.e., σ2 ≤ σ2y.
A useful quantity for characterizing the apportionment of the total variance
of the outcome between the two levels of variation is the intraclass correlation
coefficient (ICC). The ICC, commonly denoted ρ, is defined as
ρ =
σ2u
σ2y
=
σ2u
σ2u + σ
2

. (1.5)
The ICC quantifies the proportion of the total variance of the outcome that
is attributable to clustering, or more precisely, to variance of the cluster-level
means. Because σ2u and σ
2
 are non-negative, we must have 0 ≤ ρ ≤ 1.
It can be shown that, for model (1.3), ρ also equals the correlation be-
tween two different observations from the same cluster, Corr(Yij , Yi′j), i 6= i′.
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Furthermore, the covariance of two different observations from the same clus-
ter, Cov(Yij , Yi′j), is equal to ρσ
2
y. By rearranging (1.5), we also have that
σ2u = ρσ
2
y and σ
2
 = (1− ρ)σ2y.
The intraclass correlation coefficient
For two-level data following model (1.3), the intraclass correlation coef-
ficient (ICC), often denoted ρ, quantifies the proportion of the total vari-
ance of the outcome that is due to variance between clusters (i.e., variance
in cluster-level means). The ICC is also equal to the correlation between
two observations within the same cluster.
For most cluster randomized trials, ρ is small, typically in the range
of 0.001 to 0.05. The value of the ICC in any specific trial will depend
on the outcome variable, the type of cluster and other context-specific fac-
tors. Reporting guidelines recommend that cluster randomized trials report
the observed ICC [9]. Reviews compiling ICC values from various studies
include [11, 21, 44].
Now we consider sample means of data from cluster randomized trials and
their variance. This will lead to some fundamental quantities and principles.
Suppose that we have a set of n2 clusters with n1 individuals in each
cluster. This is our balanced data assumption. We discuss unequal allocation
to conditions and varying cluster sizes in Section 1.4. The sample mean for
cluster j can be calculated as
Y¯·j =
1
n1
n1∑
i=1
Yij . (1.6)
What is the variance of the sample cluster mean? Using rules for the variance
of the sum of correlated random variables, the variance can be found to be
V ar(Y¯·j) =
1
n1
[V ar(Yij) + (n1 − 1)Cov(Yij , Yi′j)] =
σ2y
n1
[1 + (n1 − 1)ρ] .
(1.7)
Let Y¯·· = 1n2
∑n2
j=1 Y¯·j =
1
n1n2
∑n2
j=1
∑n1
i=1 Yij be the overall sample mean
across all observations. Because observations in different clusters are assumed
to be independent, the variance of Y¯·· is
V ar(Y¯··) =
σ2y
n1n2
[1 + (n1 − 1)ρ] . (1.8)
If the n1n2 observations had been independent, the variance of the sample
mean would have been σ2y/(n1n2). The ratio of the variances is 1 + (n1 − 1)ρ,
which is called the design effect for cluster randomized trials. We expect that
the design effect will be greater than one when ρ > 0; hence another common
term for the design effect is the variance inflation factor. The design effect will
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reduce to 1 when we have clusters of size 1 or when ρ = 0, that is, independent
observations. The loss of statistical efficiency in cluster randomized trials is
due to the design effect, which leads to larger standard errors.
The design effect
The term design effect comes from the field of survey sampling; see, for
example, Kish [34]. When we conduct a cluster randomized trial, we can
be regarded as collecting data from a cluster sample of individuals in each
condition, rather than a simple random sample of individuals. The design
effect or Deff quantifies the increase in the variance of the sample mean
resulting from using a cluster sampling design:
Deff =
Variance for cluster sampling
Variance for simple random sampling
. (1.9)
The design effect for a cluster randomized trial following model (1.3) equals
1+(n1−1)ρ and represents the multiplicative factor by which the variance
of the sample mean is increased due to cluster sampling.
Although ρ is typically small, the design effect also depends on cluster
size and can be quite large. For example, an ICC of 0.02 and a cluster size
of 100 leads to a variance inflation factor of 2.98, i.e., almost a tripling of
the variance of the sample mean compared to independent observations.
This represents a substantial loss of statistical efficiency.
1.3.1.2 Estimation and inference
Suppose now that our n2 clusters are randomized to two conditions, with
n2/2 clusters in each condition. To accommodate different population means
in each condition, we modify the model for the mean of cluster j to be
µj = γ0 + γ1wj + uj
where wj is coded as −0.5 for the control condition and 0.5 for the intervention
condition. Thus γ0 is the grand mean (mean of the two means) and γ1 is
the difference in means between the two conditions. Note that the treatment
indicator wj is subscripted only by j and not by i, since treatment is assigned
at the cluster level. The single equation model for the outcome Yij is
Yij = γ0 + γ1wj + uj + ij . (1.10)
We have allowed clusters in different conditions to have different cluster
means but this was done using a fixed effect; we have not altered the ran-
dom effect terms in the model. The total variance of an observation is still
V ar(Yij) = σ
2
u + σ
2
 and we still express the ICC as ρ = σ
2
u/(σ
2
u + σ
2
 ), al-
though it is possible that the magnitude of the variance components differs
between conditions; we discuss this in Section 1.4.1.4.
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Interest usually focuses on estimating the treatment effect γ1. An unbiased
estimate of γ1 can be obtained as the difference of treatment group means.
Indexing condition by k = 1, 2 and the outcomes as Yijk, our estimate of the
treatment effect is
γˆ1 = Y¯··1 − Y¯··2
with variance
V ar(γˆ1) =
4σ2y
n1n2
[1 + (n1 − 1)ρ] (1.11)
(the factor of 4 arises because there are n2/2 clusters per condition). Using
(1.4) and (1.5), we can also write this variance as
V ar(γˆ1) =
4
n1n2
(
σ2 + n1σ
2
u
)
. (1.12)
The test for a treatment effect is the test of the null hypothesis H0 : γ1 = 0
in model (1.10). This test can be conducted using the test statistic
γˆ1
SE(γˆ1)
(1.13)
where SE(γˆ1) =
√
V ar(γˆ1). Under the null hypothesis, test statistic (1.13) has
approximately a t distribution. In general, for a two-level model, the number of
degrees of freedom (df) associated with the regression parameter for a cluster-
level covariate is n2 − q − 1, where q equals the total number of cluster-level
covariates. For testing γ1 in model (1.10), the df for the t statistic are n2 − 2.
When the df are large, the standard normal distribution can be used.
The parameter γ1 and its standard error, as well as γ0 and its standard
error, can be estimated by maximum likelihood or restricted maximum like-
lihood (REML). When the number of clusters is small (n2 ≤ 50), REML es-
timation is recommended for estimating fixed effect parameters; for datasets
with a larger number of clusters, either method may be used and should give
similar results [37, 57]. REML estimates are preferred for estimating the vari-
ance components σ2 and σ
2
u, regardless of dataset size, because maximum
likelihood estimators of the variance components have a downward bias [57].
If stratification is used, the model should include indicators for strata,
which ensures that the treatment effect estimates are conditional on stratum.
Stratification can increase power; see Section 1.4.1.8.
1.3.1.3 Example
To illustrate inference for a cluster randomized trial with a continuous out-
come, we simulate and analyze data based loosely on a CRT of a pain self-
management intervention for cancer patients reported in Jahn et al. [30]. The
intervention was delivered in the hospital setting and involved nurse-led coun-
seling program focused principally on reducing patient-related cognitive bar-
riers. To avoid contamination across conditions, the study was designed as a
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cluster randomized trial and the intervention was applied at the ward level.
Nurses in wards assigned to the intervention condition received special train-
ing, while nurses in control wards did not. Outcomes were measured on pa-
tients in the wards. The primary outcome was patient score on the Barriers
Questionnaire II.
While the actual trial had 9 oncology wards in each condition and a vari-
able number of patients per ward, for pedagogical reasons we simulated data
with 10 wards per condition and 10 patients per ward. Our simulated data
were based on model (1.10) with parameter values γ0 = 60, γ1 = 10, σ
2
u = 25
and σ2 = 600. These values imply that σ
2
y = 625 and ρ = 0.04. The R com-
mands to simulate the data and fit the model are
# set parameter values
n2 <- 20
n1 <- 10
gamma_0 <- 60
gamma_1 <- 10
sigma_u <- sqrt(25)
sigma_e <- sqrt(600)
sigma_y <- sqrt(625)
# simulate data
set.seed(96135)
u <- rep(rnorm(n2, sd=sigma_u), each=n1)
e <- rnorm(n1*n2, sd=sigma_e)
w <- c(rep(-0.5, n1*n2/2), rep(0.5, n1*n2/2))
y <- gamma_0 + gamma_1*w + u + e
j <- rep(seq(1:n2), each=n1)
pain.data <- data.frame(y, j, w)
# fit model
library(lme4)
paincrt <- lmer(y ~ w + (1|j), data=pain.data)
summary(paincrt)
...
Random effects:
Groups Name Variance Std.Dev.
j (Intercept) 30.3 5.51
Residual 618.7 24.87
Number of obs: 200, groups: j, 20
Fixed effects:
Estimate Std. Error df t value Pr(>|t|)
(Intercept) 63.95 2.15 18.00 29.79 <2e-16 ***
w 9.90 4.29 18.00 2.31 0.033 *
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The grand mean is estimated as γˆ0 = 63.95 while the treatment effect is
estimated as γˆ1 = 9.90 and is significant at the 0.05 level. The df for both
fixed effects parameters is 20 − 2 = 18. The estimated variance components
are σˆ2u = 30.3 and σˆ
2
 = 618.7, from which we can calculate σˆ
2
y = 649.0 and
ρˆ = 0.047. The estimated parameter values do not coincide with the true
values due to sampling variability.
What would we have inferred if we had neglected to account for the clus-
tering of observations within wards? The following R code fits the linear re-
gression model Yij = γ0+γ1wj+eij , which assumes independent observations,
to the data:
# Wrong model!
summary(lm(y ~ w , data=pain.data))
...
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 64.0 1.8 35.58 <2e-16 ***
w 9.9 3.6 2.75 0.0064 **
We get the same point estimates for γ0 and γ1, but the standard errors
are substantially smaller and hence the p-value for the treatment effect is also
lower. Although in this case we would have reached the same conclusion about
rejecting the null hypothesis of no treatment effect at level 0.05, in many data
analyses, the deflated p-value would have led us to incorrectly reject the null.
The regression parameter estimates are identical in the models fit with and
without clustering because our data are balanced; in the case of unbalanced
data, this will not always occur.
We can get confidence intervals for the variance components using the
command
confint(paincrt)
which yields a 95% confidence interval for σˆu of (0.00, 10.2). The interval
appears to include zero. Should we drop this variance component? No, as
explained in the accompanying box.
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Should nonsignificant variance components be dropped?
When analyzing data from a cluster randomized trial, if a variance
component is not significantly different from zero, should it be dropped
from the model?
Even a small ICC, if ignored, can inflate the Type I error rate, that is,
the probability that we erroneously reject the null hypothesis and declare
the intervention to be effective. Furthermore, the standard errors for vari-
ance components are not well estimated when their true values are close
to zero, and the degrees of freedom for such tests, which are based on
the number of clusters, are usually limited, which limits the power of such
tests. Therefore it is recommended that all random effects associated with
the study design and sampling plan be retained in the model.
In the example, the true value of the variance of the cluster means is
known to be non-zero because the data were simulated. Dropping this term
would lead to a misspecified model.
1.3.2 Dichotomous outcomes
Now we consider cluster randomized trials with dichotomous outcomes. Exam-
ples of dichotomous outcomes include achieving a tumor response, receiving
a cancer screening procedure or acquiring an infection.
There are two common approaches to modeling dichotomous outcomes
from cluster randomized trials [16]. One approach models the cluster-level
proportions, and the second models the cluster-level log odds. We discuss
both approaches. We spend some time discussing the intraclass correlation,
which is more complicated for dichotomous data than it is for continuous data.
We first discuss simple models for two-level clustered data, without covariates
or different intervention conditions, in order to study important principles,
and then discuss estimation and inference for an intervention effect.
1.3.2.1 Cluster-level proportions model
Let Yij denote the dichotomous outcome of the ith individual in the jth
cluster, where Yij = 1 for success and 0 for failure. Under the cluster-level
proportions model, the individuals in cluster j have a probability of success
that is specific to their cluster, denoted pij . Thus the Yij are Bernoulli random
variables with success probability pij . The cluster-level success probabilities pij
are assumed to be random variables that follow a distribution with E(pij) = pi
and V ar(pij) = σ
2
d. The specific distribution does not affect the key results
and we leave it unspecified. Under this model, the mean and variance of Yij ,
unconditional on cluster, are E(Yij) = E(pij) = pi and V ar(Yij) = pi(1 − pi).
This leads to an expression for the ICC in the cluster-level proportions model
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as
ρd =
V ar(pij)
V ar(Yij)
=
σ2d
pi(1− pi) . (1.14)
Now we consider sample proportions and their properties. The sample pro-
portion for cluster j can be calculated as
pˆij = Y¯·j =
1
n1
n1∑
i=1
Yij ,
where n1 is cluster size. The sample cluster proportion is an unbiased estimate
of the true cluster proportion, E(pˆij) = pij , and the variance of pˆij can be found
to be
V ar(pˆij) =
pi(1− pi)
n1
[1 + (n1 − 1)ρd] .
This variance is the analogue of the variance of the sample cluster mean for
continuous outcomes given in equation (1.7).
Let pˆi = Y¯·· = 1n1n2
∑n2
j=1
∑n1
i=1 Yij be the overall sample proportion across
all observations, assuming n2 clusters of size n1. The overall sample proportion
provides an unbiased estimate of population proportion; E(pˆi) = pi. Because
observations in different clusters are assumed to be independent, the variance
of pˆi is
V ar(pˆi) =
pi(1− pi)
n1n2
[1 + (n1 − 1)ρd] . (1.15)
Had the n1n2 observations been independent, the variance of the sample pro-
portion would have been pi(1−pi)n1n2 . As for continuous outcomes, the ratio of the
variances is the design effect, 1 + (n1 − 1)ρd, which reflects the increase in
the variance of the sample proportion attributable to correlation of observa-
tions within clusters, or from another perspective, due to cluster sampling of
observations.
Now suppose that our n2 clusters are randomized to two conditions with
n2/2 clusters in each condition. Denote the success proportions in the two
conditions as pi1 and pi2. Adding a subscript k to denote condition, we could
estimate these proportions as pˆik = Y¯··k = 1n1n2/2
∑n2/2
j=1
∑n1
i=1 Yijk for k = 1, 2.
The intervention effect can be estimated as the difference in sample propor-
tions, pˆi1 − pˆi2, and its variance is
V ar(pˆi1 − pˆi2) =
[
pi1(1− pi1)
n1n2/2
+
pi2(1− pi2)
n1n2/2
]
[1 + (n1 − 1)ρd] . (1.16)
This result is the basis for a commonly used sample size calculation ap-
proach for cluster randomized trials with dichotomous outcomes, which we
discuss in section 1.4.2.1. However, the cluster-level log odds model, which we
discuss next, is more commonly used for analysis.
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1.3.2.2 Cluster-level log odds model
The other approach for modeling dichotomous outcomes for CRTs is to use
a random effects logistic regression model, such as the logistic-normal model.
This model assumes that Yij is Bernoulli with cluster-specific success proba-
bility pij , and that the logits of cluster proportions pij follow a normal distri-
bution. The basic model without covariates can be expressed as
log
(
pij
1− pij
)
= γ0 + uj (1.17)
where uj ∼ N(0, σ2u).
Under this model, the between-cluster variance σ2u is expressed on the log-
odds scale. The model implicitly assumes an overall population proportion
pi = 1/(1 + e−γ0), making the total population outcome variance equal to
pi(1 − pi), which is on the proportions scale. The quantities σ2u and pi(1 − pi)
are not comparable because they are on different scales and it is not sensible
to form an ICC as their ratio. One way of finding an ICC for model (1.17)
that is on the proportions scale is to use a Taylor expansion of logit(pij), which
yields an approximation of ρd as
ρd ≈ σ2u[pi(1− pi)]2; (1.18)
see [61]. An alternative approach is to define the ICC on the log-odds scale.
This leads to the expression
ρd(l) =
σ2u
σ2u + Π
2/3
(1.19)
where Π is the mathematical constant 3.14156...; see [16, 57]. The term Π2/3
is the variance of the standard logistic distribution and plays the role of the
within-cluster variance.
ICCs for dichotomous data
The ICC for clustered dichotomous data can be defined on the pro-
portions scale (ρd) or the log odds scale (ρd(l)). These ICCs can take very
different values for the same data. The proportional discrepancy between
ρd and ρd(l) is greater for larger values of ρd and when the prevalence pi is
farther from 0.5. For further discussion, see [16].
Researchers should be aware of the two different scales for the ICC for
clustered dichotomous data and be careful to use the ICC on the correct
scale for sample size and power calculations.
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1.3.2.3 Estimation and inference
To model data from a cluster randomized trial, we use the cluster-level log
odds model and expand the model to include a covariate encoding cluster
condition. The model is
log
(
pij
1− pij
)
= γ0 + γ1wj + uj (1.20)
where wj is coded as -0.5 for the control condition and 0.5 for the intervention
condition. Thus γ0 is the average log odds of success across all clusters and
γ1 is the difference in log odds for success between the two conditions. The
intervention effect is typically reported as an odds ratio, obtained as eγ1 .
A closed form expression for the estimator γˆ1 and its variance can be
derived; see [42, 58]. Assuming equal-sized clusters of size n1 and n2/2 clusters
per condition, the intervention effect can be estimated as the difference in
average log odds between conditions and the variance of γˆ1 can be estimated
as
V ar(γˆ1) =
4(σ2u + τ
2/n1)
n2
(1.21)
where
τ2 =
1
2
[
1
pi1(1− pi1) +
1
pi2(1− pi2)
]
(1.22)
is a measure of variability at the individual level.
There are various algorithms for fitting mixed-effects logistic models and
obtaining parameter estimates, standard errors and confidence intervals [33].
The expression for the likelihood of a mixed-effects model is an integral over
the random effects space. For a linear mixed-effects model, this integral can be
evaluated exactly. For a generalized linear mixed-effect models, the integral
must be approximated. Different approximation methods can give slightly
different results.
1.3.2.4 Example
To illustrate analysis for a cluster randomized trial with a dichotomous out-
come, we simulate data based on the Breast Cancer Education Program for
Samoan Women [39]. This study evaluated the effectiveness of a breast cancer
education program tailored to women with Samoan ancestry in the United
States. In the trial, 61 Samoan churches were randomized to the intervention
or control condition. Women from churches in the intervention arm partici-
pated in culturally tailored interactive group discussion sessions with a health
educator; the control condition was usual care. The primary outcome was
self-reported receipt of a mammogram within eight months.
The trial had a variable number of women per church, ranging from 1 to
42 with a median of 13. For simplicity, we simulated data with 30 churches in
each condition and 12 participants per church. The trial had a rather high ICC
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of 0.19 on the proportions scale (ρd). We simulated data with ρd = 0.1. We
assume that the proportions of participants with self-reported mammogram
receipt are 0.30 and 0.50 in the control and intervention arms, respectively.
The overall population proportion is thus 0.40, and using equation (1.18), we
find that we need to set σu = 1.318. Using equation (1.19), the ICC on the log
odds scale is ρd(l) = 0.345 (note that this value differs substantially from the
ρd of 0.1). The regression coefficients needed to reflect the success proportions
in each arm are γ0 = −0.4237 and γ1 = 0.8473. R code to simulate data is
# set parameter values
n2 <- 60
n1 <- 12
gamma_0 <- -0.4236
gamma_1 <- 0.8473
sigma_u <- 1.318
# simulate outcome data
set.seed(32410)
linprobs1 <- gamma_0-gamma_1/2+rep(rnorm(n2/2, sd=sigma_u), each=n1)
linprobs2 <- gamma_0+gamma_1/2+rep(rnorm(n2/2, sd=sigma_u), each=n1)
linprobs <- c(linprobs1, linprobs2)
probs <- 1/(1+exp(-linprobs))
y <- sapply(probs, function(x) sample(0:1, 1, prob = c(1-x, x)))
j <- rep(seq(1:n2), each=n1)
w <- c(rep(-0.5, n1*n2/2), rep(0.5, n1*n2/2))
mamm.data <- data.frame(y, j, w)
# average success proportions in each condition
mean(mamm.data$y[mamm.data$w==0.5])
mean(mamm.data$y[mamm.data$w==-0.5])
The success proportions in the simulated data are 0.36 and 0.49 in the
control and intervention arms, respectively. Figure 1.1 shows the distribution
of the cluster proportions and the logits of the cluster proportions in the two
study arms. The proportions and logits are shifted somewhat lower for the
control clusters. The logits of the cluster proportions are specified as normally
distributed with different means in each condition; the normality assumption
is not fully apparent in the figure, particularly in the control arm, due to the
relatively low number of clusters in each condition.
R code to fit the model using glmer in R and abbreviated output are below:
# fit model
summary(glmer(y ~ w + (1 | j), data = mamm.data, family = binomial))
...
Random effects:
Groups Name Variance Std.Dev.
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FIGURE 1.1
Distribution of cluster-level proportions and logits of the cluster-level propor-
tions from simulated data, by intervention condition.
j (Intercept) 1.71 1.31
Number of obs: 720, groups: j, 60
Fixed effects:
Estimate Std. Error z value Pr(>|z|)
(Intercept) -0.418 0.192 -2.18 0.029 *
w 0.694 0.384 1.81 0.071 .
The test statistics for the fixed effects have approximately a normal distribu-
tion rather than a t distribution under the null, so there are no df to consider.
The estimates differ from the true values due to sampling variability. The p-
value exceeds the benchmark of 0.05. The odds ratio for the treatment effect
is e0.694 = 2.0. The estimated standard deviation of the random effect is 1.31.
Using (1.19) and (1.18), we can calculate the estimated ICCs as 0.342 on the
log odds scale and 0.098 on the proportions scale. These are close to the true
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values. The discrepancy between these two ICCs serves as a reminder that
these two quantities are on different scales and should not be confused.
1.3.3 Other analysis methods
We have discussed analysis of data from CRTs using multilevel modeling (gen-
eral or generalized linear mixed models). This approach is statistically efficient
and easily accommodates regression adjustment for covariates or specifica-
tion of additional hierarchical data structure. Other methods may be useful
for specific studies. For example, a two-sample t test comparing cluster-level
summary statistics (means, proportions) is robust to departures from the nor-
mality assumption [23]. Other robust options include nonparametric tests on
cluster-level statistics and permutation tests. Some of these methods allow for
a limited amount of covariate adjustment. For further information, see [23].
Another approach is generalized estimating equations (GEE) [14, 35]. GEE
assumes a linear or generalized linear model for the expected values of the de-
pendent variable, conditional on the explanatory variables, but does not fully
specify a probability model for the data. Rather, the parameters are estimated
under a “working model” for the covariance structure; for a cluster randomized
trial, an exchangeable correlation structure is typically assumed. Standard er-
rors are obtained using a robust sandwich estimator. For our example, the R
code and abbreviated output are
summary(geeglm(y ~ w, id=j, data=mamm.data, family=binomial,
corstr= "exchangeable"))
...
Coefficients:
Estimate Std.err Wald Pr(>|W|)
(Intercept) -0.319 0.148 4.64 0.031 *
w 0.527 0.296 3.17 0.075 .
...
Estimated Correlation Parameters:
Estimate Std.err
alpha 0.253 0.0476
The coefficient estimates in a GEE model are population-average estimates;
here the estimated population-average odds ratio is e0.527 = 1.7. In contrast,
mixed-effects logistic models provide odds ratios conditional on cluster. In
general, population-averaged odds ratios are closer to the null than are cluster-
conditional odds ratios. However, the p-values tend to be similar. Here, the
p-values are close. The GEE estimated correlation parameter is the Pearson
correlation between observations in the same cluster. For further discussion of
population-average versus cluster-specific approaches, see [19, 27].
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1.4 Sample Size and Power
When designing a cluster randomized trial or other study, we typically want
to ensure that the sample size will be adequate to achieve the study’s objec-
tives. The primary objective is usually to detect a clinically meaningful and
statistically significant difference between outcomes in the intervention and
control conditions.
This section discusses how to calculate statistical power for a cluster ran-
domized trial with a continuous or binary outcome, and how to find the sample
size required to achieve a desired level of power. For both types of outcomes,
results are first derived for the case of balanced data, with equal numbers of
clusters in each condition and clusters of equal size. Subsequent sections con-
sider unequal allocation of clusters, varying cluster sizes, and unequal ICCs
in the two arms.
We restrict attention to cluster randomized trials with two-level data struc-
ture and a continuous or binary outcome. Discussion of power and sample size
for other cluster randomized trial designs and other types of outcomes can be
found in [8, 12, 15, 23, 41, 43, 53].
1.4.1 Continuous outcomes
1.4.1.1 Power
We begin by assuming that our data follow the two-level normal model (1.10),
under which the observation Yij , for individual i in cluster j, follows
Yij = γ0 + γ1wj + uj + ij
with uj ∼ N(0, σ2u), eij ∼ N(0, σ2 ), and uj and ij independent. We test for an
intervention effect by testing H0 : γ1 = 0 using test statistic (1.13). When the
null hypothesis is true, the test statistic follows a t distribution with n2 − 2
degrees of freedom. When γ1 6= 0, the test statistic follows a noncentral t
distribution (see box), which has two parameters, a df and a noncentrality
parameter. Here, the df are n2 − 2 and when there are n2/2 clusters in each
condition, n1 individuals in each cluster and equal ICCs in each arm, the
noncentrality parameter is
λ =
γ1√
4(σ2+n1σ
2
u)
n1n2
=
γ1√
4σ2y [1+(n1−1)ρ]
n1n2
. (1.23)
The numerator is the true difference in means between conditions and the
two versions of the denominator are the square root of the variance of γˆ1; see
Section 1.3.1.2.
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Noncentral t distribution
A random variable of the form
Z + λ√
χ2ν
ν
(1.24)
where Z is a standard normal random variable, χ2ν is a chi-square random
variable with ν degrees of freedom and λ is a constant, has a noncentral
t distribution with ν degrees of freedom and noncentrality parameter λ,
denoted tν,λ. The standard (central) t distribution is the special case of
λ = 0.
It is often convenient to work with standardized effect sizes, which give the
difference between the intervention and control condition means in units of the
standard deviation of the outcome variable. Here, the standardized effect size
is δ = γ1/σy, where σ
2
y is the total variance of the outcome. The noncentrality
parameter can then be expressed as
λ =
δ√
4[1+(n1−1)ρ]
n1n2
. (1.25)
Benchmarks for standardized effect sizes are given by Cohen [10], who sug-
gested that 0.2, 0.5 and 0.8 represent small, moderate and large effect sizes.
The power 1 − β of a hypothesis test is the probability that the value of
the test statistic is more extreme than the critical value(s) given that some
specified scenario is true. For a two-sided test with Type I error rate α, the
power for a CRT following the two-level normal model (1.10) can be calculated
as
P [tn2−2,λ > tn2−2,0(1− α/2)] + P [tn2−2,λ < tn2−2,0(α/2)] (1.26)
where tν,0(a) denotes the ath quantile of the standard t distribution. One
of these tail probabilities will typically be very small and can be neglected.
When the noncentrality parameter λ is expressed as in equation (1.23), the
parameter values required to compute power are n1, n2, γ1, and either σ
2

and σ2u or σ
2
y and ρ. When λ is expressed as in (1.25), the parameter values
required are n1, n2, δ and ρ.
An R function to calculate power for a two-level, normal outcome CRT
with balanced data and a two-sided test is
power.crt.bal <- function(delta, rho, n1, n2, alpha){
ta <- qt(1-alpha/2, n2-2)
tb <- qt(alpha/2, n2-2)
deff <- 1 + (n1-1)*rho
lambda <- delta/sqrt(4*deff/(n1*n2))
df <- n2-2
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FIGURE 1.2
Illustration of power calculation. Parameter values are δ = 0.4, ρ = 0.02,
n1 = 10 and n2 = 20. Density on the left represents the distribution of the
test statistic under the null, a (central) t distribution with 18 df. Density on
the right represents its distribution under the alternative, a noncentral t with
18 df and noncentrality parameter 2.604. Dashed vertical lines indicate the
critical values. Shaded area represents power.
pow <- pt(ta, df, lambda, lower.tail=FALSE) + pt(tb, df, lambda)
print("Deff is")
print(deff)
print("Power is")
return(pow)
}
power.crt.bal(0.4, 0.02, 10, 20, 0.05)
Using this function, we can find that the power for a trial with an effect size
of δ = 0.4, ρ = 0.02, n1 = 10 individuals per cluster and n2 = 20 total clusters
is 0.69 and the design effect is 1.18. The relationship between the distribution
of the test statistic under the null and alternative hypotheses for this example
is depicted in Figure 1.2.
What factors affect the power of a cluster randomized trial? As |λ| in-
creases, the noncentral t distribution moves farther away from zero and power
increases. The factors affecting power can thus be gleaned from the expres-
sions for the noncentrality parameter in (1.23) and (1.25). Power increases as
the treatment effect |γ1| increases and decreases as any of the variance param-
eters σ2y, σ
2
u or σ
2
 or ρ increase, all else being equal. What happens to power
as we increase cluster size n1 or number of clusters n2? To investigate this,
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we rewrite V ar(γˆ1) as
V ar(γˆ1) = 4
(
σ2
n1n2
+
σ2u
n2
)
. (1.27)
As n2 increases, both components of the variance decrease; as n2 → ∞,
V ar(γˆ1) → 0, λ → ±∞ and power → 1. However, increasing cluster size
n1 only reduces the first component; it has no effect on the influence of the
variance of the cluster means. As n1 → ∞, V ar(γˆ1) → σ2u/n2. Thus at some
point, increasing the number of individuals per cluster will have a negligible
effect on power. In general, power for CRTs is driven more by number of
clusters than by cluster size.
Power: number of clusters versus cluster size
In general, the power of a cluster randomized trial is influenced more
strongly by the number of clusters than by the number of individuals per
cluster. To increase power, increasing the number of clusters is usually a
more effective strategy than increasing cluster size.
1.4.1.2 Sample size: number of clusters
Suppose that we wish to determine the number of clusters required to achieve a
desired level of power. The size of the clusters is assumed known and constant.
Equation (1.26) provides power as a function of total number of clusters n2;
however, we cannot simply invert the equation and solve for n2 as a function
of power because n2 appears in both the noncentrality parameter of the t
distribution and the degrees of freedom. However, the equation can be solved
iteratively until the minimum n2 that provides sufficient power is identified.
Note that for equal allocation of clusters to study arms, n2 must be an even
number.
When the number of clusters and therefore the df are sufficiently large
(n2 ≥ 30 or so), the normal approximation to the t can be used. Using this
approach, the minimum total number of clusters required, with n2/2 in each
condition, can be calculated as
n2 ≥ 4
(z1−α/2 + z1−β)2
n1δ2
[1 + (n1 − 1)ρ] , (1.28)
where zp represents the pth quantile of the standard normal distribution and
we assume a two-sided test with Type I error rate α. The calculated value
of n2 will need to be rounded to the next highest even integer to achieve an
equal number of clusters in each arm. The following R function computes the
sample size:
sampsize.crt.bal <- function(delta, rho, n1, beta, alpha){
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za <- qnorm(1-alpha/2)
zb <- qnorm(1-beta)
n2 <- 4*(za+zb)^2*(1+(n1-1)*rho)/(n1*delta^2)
print("Total number of clusters required calculated as")
print(n2)
print("Required clusters per arm is")
print(ceiling(n2/2))
}
Example. Suppose we wish to find the minimum number of clusters required
to detect a small effect size of 0.2 with 80% power assuming an ICC of 0.05,
clusters of size 25 and Type I error rate of 0.05. Using the command
sampsize.crt.bal(0.2, 0.05, 25, 0.2, 0.05)
we find that n2 is calculated as 69.1 clusters, which we round up to 70 total
clusters (35 per condition) to ensure at least 80% power.
Some authors suggest that when the number of clusters and therefore the
df for the t distribution are small, one additional cluster per arm should be
added to the value calculated by equation (1.28) to account for using the
normal rather than the t distribution; see [23]. In general, a more accurate
calculation can be performed using the power equation (1.26) iteratively.
Example. To detect a larger effect size of δ = 0.6, using equation (1.28),
we calculate n2 ≥ 7.7. This number is low enough that we are concerned about
using the normal approximation to the t distribution. Using power formula
(1.26) to get a more precise result, we calculate that for 8 total clusters the
power is 67%, whereas for 10 total clusters the power is 80%. Thus we need
10 clusters in total.
If we drop the design effect from sample size formula (1.28) and rearrange
terms, we arrive at
N = n1n2 ≥ 4
(z1−α/2 + z1−β)2
δ2
, (1.29)
which provides the minimum required total sample size N for a two-sample
t test with equal variances and equal-sized samples n1n2/2 in each group,
assuming large samples. The difference is the design effect. A common rubric
for calculating the sample size required for a cluster randomized trial is to
calculate the sample size for a trial involving independent observations and
then inflate by the design effect. This approach leads to formula (1.28).
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Variance inflation approach to sample size calculation for
cluster randomized trials
A common approach for calculating the sample size for a cluster ran-
domized trial to achieve a desired level of power is to calculate the sample
size requirement assuming independent observations and then inflate this
number by the design effect:
Total N for cluster randomized trial
≈ Total N for individually randomized trial×Deff. (1.30)
While this approach can give a good approximation, it is recommended
that other factors that may affect power be considered, such as varying
cluster sizes, unequal ICCs and covariates.
Example. Using the variance inflation approach, for δ = 0.2 for an indi-
vidually randomized trial, we need 785 total subjects to achieve 80% power.
For n1 = 25 and ρ = 0.05, the design effect is 1+(n1−1)ρ = 2.2, so we inflate
the total sample size to 1,727. Clusters are of size 25, so this total number of
observations corresponds to 69 clusters, which we round up to a total of 70,
or 35 in each arm.
1.4.1.3 Sample size per cluster
In some situations, we may have a fixed number of clusters available but have
a choice as to the number of observations to sample from each cluster. To
determine the number of observations to sample from each cluster to achieve
a desired level of power, we can solve (1.28) for n1, which yields
n1 =
4(1− ρ)
n2δ2
(z1−α/2+z1−β)2
− 4ρ . (1.31)
An R function to calculate sample size per cluster is
sampsizeper.crt.bal<-function(delta, rho, n2, beta, alpha){
za <- qnorm(1-alpha/2)
zb <- qnorm(1-beta)
n1 <- 4*(1-rho)/((n2*delta^2/(za+zb)^2) - 4*rho)
return(n1)
}
Example. Suppose we have 12 hospitals willing to participate in a study and
we wish to know how many patients to sample from each hospital to achieve
80% power to detect an effect size of δ = 0.5, assuming ρ = 0.05. The R
command
sampsizeper.crt.bal(0.5, 0.05, 12, 0.2, 0.05)
Cluster Randomized Trials 25
calculates n1 = 20.9, indicating that we need 21 patients per cluster.
It will not always be possible to achieve a desired level of power with a
fixed number of clusters, even when using an arbitrarily large cluster size.
Indeed, the solution for n1 will be negative if n2 < 4ρ(z1−α/2 + z1−β)2/δ2,
reflecting the impossibility of always achieving desired power by increasing
cluster size. The influence of cluster number versus cluster size on power is
discussed in Section 1.4.1.1.
1.4.1.4 Unequal ICCs in treatment arms
Thus far we have made the implicit assumption that σ2y and ρ, or equivalently
σ2u and σ
2
 , are the same across arms. In some studies, we might expect the
variance or correlation parameters to differ across arms. For example, an in-
tervention that encourages interaction among cluster members may result in
a higher ICC in the intervention arm, or heterogeneity in the uptake of the
intervention may increase the variance of the outcome in the intervention arm.
When we expect different ICCs in the two treatment arms, the variance of
the treatment effect estimate is, assuming balanced data,
V ar(γˆ1) =
2σ2y
n1n2
{[1 + (n1 − 1)ρ1] + [1 + (n1 − 1)ρ2]} , (1.32)
which simplifies to equation (1.11) when ρ1 = ρ2. This expression can be used
in the formula for the noncentrality parameter to calculate power. Using the
normal approximation, the total number of clusters required (with n2/2 in
each condition) can be calculated as
n2 ≥ 2
(z1−α/2 + z1−β)2
n1δ2
{[1 + (n1 − 1)ρ1] + [1 + (n1 − 1)ρ2]} . (1.33)
1.4.1.5 Unequal allocation
Thus far, we have considered only trials with equal numbers of clusters in each
arm. Unequal allocation can also be considered. Reasons that investigators
may choose to use unequal allocation include reducing overall costs when one
condition is more expensive to implement than the other, or to make trial
participation more attractive by having a higher probability of being assigned
to the intervention condition.
Let r denote the proportion of clusters allocated to arm 1. Then the num-
bers of clusters allocated to arms 1 and 2 are rn2 and (1− r)n2, respectively,
and the variance of the treatment effect estimate becomes
V ar(γˆ1) =
σ2y [1 + (n1 − 1)ρ]
n1n2
(
1
r
+
1
1− r
)
=
σ2 + n1σ
2
u
n1n2
(
1
r
+
1
1− r
)
.
(1.34)
The noncentrality parameter can be computed by using the square root of
this expression for the denominator in equation (1.23) or (1.25).
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Optimal allocation. For a given effect size, power will be maximized
when V ar(γˆ1) is minimized. If we minimize equation (1.34) with respect to
r, we obtain r = 0.5, which corresponds to equal allocation. However, the
formula assumes that σ2y and ρ, or σ
2
u and σ
2
 , are the same across arms. If
we allow different ICCs and unequal allocation, the variance of the treatment
effect estimate is
V ar(γˆ1) =
σ2y
n1n2
[
1 + (n1 − 1)ρ1
r
+
1 + (n1 − 1)ρ2
1− r
]
. (1.35)
The optimal allocation, optimal in the sense of minimizing the variance, can
be found to be
√
d1/(
√
d1 +
√
d2), where the dk are the design effects, dk =
1 + (n1 − 1)ρk, k = 1, 2. For example, with ICCs of 0.02 and 0.06 for control
and intervention and a cluster size of 50, the variance (and standard error)
are minimized and the power is maximized if we allocate 41% of the clusters
to the control condition and 59% to the intervention condition. In general,
optimal allocation will involve allocating more clusters to the condition with
the higher design effect (and thus higher variance).
Another optimal design strategy is to maximize cost efficiency, defined as
the precision (inverse variance) of the treatment effect estimate divided by
total study cost. Discussion of such designs can be found in [65]. Additional
discussion of cluster randomized designs involving costs can be found in [41].
Unequal allocation of clusters to conditions
When the ICCs are equal in the two treatment arms, maximal power
for a cluster randomized trial with a continuous outcome can be achieved
by allocating clusters equally to each treatment arm. When the ICCs are
different in the two arms, an optimal unequal allocation that maximizes
power can be found. The optimal allocation will involve allocating more
clusters to the condition with the higher design effect.
1.4.1.6 Covariates
Regression adjustment for covariates is often used in randomized trials to
improve precision. In a linear regression model for independent observations,
the effect of covariate adjustment is
σ2 = σ
2
y(1−R2Y |X) (1.36)
where σ2y is the total variance of Y , σ
2
 is the residual variance, and R
2
Y |X is the
proportion of the variance of Y that is explained by the covariates, represented
by X. Because the residual variance is a key component of the standard errors
of the regression coefficients, covariates that are strongly associated with the
outcome variable can increase precision by reducing the residual variance.
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Covariates might include demographic characteristics such as age and sex or
clinical factors associated with prognosis such as cancer stage. One particularly
notable covariate is the outcome variable measured at baseline; for example,
a trial might administer a symptoms scale to patients at baseline and at
follow up. In such trials, the data are typically analyzed using an analysis of
covariance (ANCOVA), which tests for a mean difference between conditions
in the outcome variable controlling for the baseline value of the variable.
Covariate adjustment can also be used in cluster randomized trials, but
its effects are more complicated because of the multilevel data structure. In
particular, the effects of covariates at the individual level and cluster level are
different. We discuss covariates at each level.
Cluster-level covariates. A cluster-level covariate might be the gender
or specialty of a health care provider in a trial randomizing providers, or the
percentage of pupils below the poverty line in a trial randomizing schools.
When a cluster-level covariate is added, the model becomes
Yij = γ˜0 + γ˜1wj + γ˜2zj + u˜j + ˜ij (1.37)
where tildes are used to indicate that the value of the regression coefficients
and random terms may be different in the adjusted model. We denote the
variance components in the adjusted model as σ˜2u and σ˜
2
 . How do σ˜
2
u and σ˜
2

compare to σ2u and σ
2
 ? Since a cluster-level covariate takes the same value for
all members of a cluster, it cannot explain variation among individuals within
a cluster. Therefore the within-cluster variance is unchanged and σ˜2 = σ
2
 .
For the cluster-level variance, we have
σ˜2u = (1− ρ2B)σ2u, (1.38)
where ρB is the between-cluster residual correlation between the outcome
and the covariate. Using equation (1.38) and the relationships σ2u = ρσ
2
y,
σ2 = (1− ρ)σ2y and σ2y = σ2u + σ2 , we can get an expression for the standard
error of the treatment effect estimator as
SE(ˆ˜γ1) =
√
4(σ2 + n1σ˜
2
u)
n1n2
=
√
4σ2y {1 + [n1(1− ρ2B)− 1]ρ}
n1n2
, (1.39)
where the quantity in braces is the design effect when a cluster-level covariate
is included, which simplifies to the standard design effect when ρB = 0. The
total number of clusters required to achieve power of 1− β is
n2 ≥ 4
(z1−α/2 + z1−β)2
n1δ2
{
1 + [n1(1− ρ2B)− 1]ρ
}
. (1.40)
Because 1 − ρ2B ≤ 1, we have 1 + [n1(1 − ρ2B) − 1]ρ ≤ 1 + (n1 − 1)ρ; i.e.,
the design effect is reduced. Thus adjusting for a cluster-level covariate can
be beneficial in reducing the required sample size. For example, for ρB = 0.6,
n1 = 500 and ρ = 0.05, the design effect is reduced from 25.95 to 16.95 by
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including the covariate, a reduction of 35%. When n1 = 5 or n1 = 50, the
reductions are 7.5% and 26%, respectively,
Including a cluster-level covariate comes at the expense of reducing the
df in the t statistic for the test of the intervention effect. For each covariate
term, one additional df is lost (recall that the df are n2 − q − 1, where q is
the number of cluster-level covariates, including the covariate encoding inter-
vention assignment). This effect is negligible if the number of clusters is large,
but can be important if the number of clusters is limited.
Individual-level covariates. Now we consider adjusting for an
individual-level baseline covariate, denoted cij . The covariate could be the
baseline measurement of the outcome variable, in which case the analysis
becomes an ANCOVA, or it could be other covariates associated with the
outcome. In this case, the relationships between the adjusted and unadjusted
variances are [40]
σ˜2 =
(
1− n1
n1 − 1ρ
2
W
)
σ2 and σ˜
2
u =
(
1− ρ2B +
1
n1 − 1ρ
2
W
)
σ2u (1.41)
where ρW and ρB are the within-cluster and between-cluster residual corre-
lations between the outcome Yij and the covariate cij , respectively; see [40].
These results show that the addition of the covariate can decrease the within-
cluster variance but could increase or decrease the between-cluster variance;
an increase occurs when ρ2B < (1/(n1 − 1)ρ2W ). This counterintuitive result
is discussed in [56, 57]. However, when σ2 > σ
2
u, any increase in σ
2
u will be
outweighed by the decrease in σ2 and overall the variance will be reduced [40].
This condition is expected to hold true for most CRTs.
The total required number of clusters can be found by using as the design
effect
1 + [n1(1− ρ2B)− 1]ρ−
n1ρ
2
W (1− 2ρ)
n1 − 1 . (1.42)
When individual-level covariates are entered into the model, no df are lost
from the test of the intervention effect.
As an example, suppose the outcome variable is a symptoms score and
the planned outcome analysis is an ANCOVA that adjusts for the baseline
value of the score. The correlation between the baseline and follow up scores
is expected to be about ρW = 0.7. If you lack a good estimate for the residual
correlation between clusters (ρB), a conservative estimate is 0. For n1 = 10
and ρ = 0.05, inclusion of the covariate would reduce the design effect from
1.45 to 1.045, corresponding to a reduction of 28% in the required sample size.
Somewhat different formulas for the effect of individual-level covariates
have been presented by other authors [6, 48, 60].
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Covariate adjustment in cluster randomized trials
Covariate adjustment can be an effective strategy to increase power in
a cluster randomized trial. Both cluster-level and individual-level covari-
ates that are correlated with the outcome variable can reduce the residual
variance of the outcome and thereby increase the precision of the treat-
ment effect estimator. Adding cluster-level covariates reduces the degrees
of freedom for the test of the intervention effect. If the df available for the
test of the intervention effect are limited (e.g., <30), cluster-level covariates
should be restricted to those that are highly prognostic of the outcome to
avoid loss of power.
1.4.1.7 Varying cluster sizes
Until now, we have assumed that all clusters have the same number of mem-
bers. In practice, the sizes of clusters (schools, hospitals, villages, patients
with the same health care provider) are likely to vary naturally. In addition,
clusters that were of equal size at the beginning of a trial may experience
non-response or dropout that leads to unequal cluster sizes in the final data
set.
It has been shown that, given the same total number of clusters and number
of participants, unequal cluster sizes are less efficient for estimating treatment
effects than are equal cluster sizes [2]. Thus when cluster sizes vary, efficiency
and power are reduced, and to achieve the same power, the sample size must
be enlarged.
Let θ and τ denote the mean and standard deviation of the distribution
of cluster sizes, respectively. An approximation of the relative efficiency of
unequal versus equal cluster sizes is
RE ≈ 1− λ(1− λ)CV 2 (1.43)
where λ = θθ+(1−ρ)/ρ and CV is the coefficient of variation of the cluster size
distribution, CV = τ/θ [62]. The required total number of clusters can be
obtained as the sample size assuming equal cluster sizes multiplied by 1/RE
(note that the design effect is the inverse of the relative efficiency, and 1/RE
is the design effect here). Other authors [1, 32, 36] have derived somewhat
different estimates of the relative efficiency, all of which also depend on the
ICC and CV of the cluster size distribution.
Investigators typically have a good idea of θ, the expected mean cluster
size. To estimate the standard deviation of cluster size, a strategy is to esti-
mate the minimum and maximum cluster size and approximate the standard
deviation as one fourth of the range, i.e., τ ≈ (max−min)/4.
As an example, suppose that the mean cluster size is 16 and the ICC is 0.04.
Standard deviations of cluster size of 0 (equal sizes), 4, 8 and 16 correspond
to CV s of cluster size distribution of 0, 0.25, 0.5 and 1, and estimated relative
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efficiencies of 1, 0.985, 0.94 and 0.76, respectively. The inverse REs are 1,
1.015, 1.064 and 1.32, meaning the sample sizes need to be inflated by 0%,
1.5%, 6.4% and 32%.
Unequal cluster sizes
When cluster sizes vary, efficiency and power are reduced. The loss of
efficiency increases as the dispersion of cluster sizes, as measured by the
coefficient of variation of the cluster size distribution, increases. The sample
size required to achieve the desired level of power can be found by inflating
the sample size requirement calculated assuming equal cluster sizes by the
inverse of the relative efficiency, which can be approximated using equation
(1.43).
1.4.1.8 Matching and stratification
In Section 1.2.1, we discussed how matching and stratification can be helpful
in promoting balance between arms on prognostic factors. Stratification or
matching prior to randomization can also improve power when these designs
are used in conjunction with a stratified or matched analysis. In such an analy-
sis, comparisons between conditions are made within strata. If clusters within
strata are very similar, these comparisons will be akin to comparing the same
experimental units under two different conditions. This reduces the between-
cluster variability in the estimation of the intervention effect, reducing the
standard error and increasing power.
The main impact of stratification in a CRT is to reduce the between-cluster
variance component, σ2u [15]. Because clusters in different conditions are now
compared within strata, σ2u is replaced with the variance among clusters within
strata, which we denote σ2um. The variance of the treatment effect estimator
becomes
V ar(γˆ1) =
4
(
σ2 + n1σ
2
um
)
n1n2
(1.44)
and the total number of clusters required is
n2 ≥
4(z1−α/2 − z1−β)2
n1γ21
(σ2 + n1σ
2
um); (1.45)
see [12]. Alternatively, we can define ρm as the correlation between cluster-
level means within strata or matched pairs, equal to σ2um/(σ
2
um+σ
2
 ), and the
formula becomes
n2 ≥
4σ2y(z1−α/2 − z1−β)2
n1γ21
[1 + (n1 − 1)ρ− n1ρmρ]. (1.46)
Thus the design effect is reduced by a factor of n1ρmρ. These formulae apply
to studies with matched pairs and with larger strata.
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Degrees of freedom will be lost when the stratification factors are used as
covariates in a multilevel analysis model, which is needed in order to estimate
the treatment effect within strata. Some authors suggest adding two additional
clusters per study arm in matched-pair designs and 1-2 additional clusters per
arm in designs with larger strata to account for the loss of df [23]. Because
of the loss of df, for CRTs with a small number of clusters, pair matching
should only be done if the clusters can be matched on factors that are highly
correlated with the outcome variable; see [23] for further discussion, including
a table showing the break-even values of the matching correlation above which
pair matching will provide greater power than an unmatched trial.
Example. Suppose we wish to detect a small effect size of δ = 0.2 with
power of 80% and α of 0.05 two-sided, where clusters are of size n1 = 25 and
ρ = 0.05. We found in Section 1.4 that for an unstratified design, the design
effect was 2.2 and the total number of clusters needed was 70. Suppose we
consider stratification on cluster type and anticipate a correlation of ρm = 0.3
within strata. In this case, the design effect is reduced by 25×0.3×0.05 = 0.375
and becomes 1.825. We will need a total of 1,433 individuals, or 58 clusters.
Thus the number of clusters is reduced by 17%.
The matching correlation ρM can be difficult to predict. In the face of
uncertainty about ρM , a conservative approach is to ignore any gain in power
due to stratification.
Effect of matching and stratification on power
In a stratified design, comparisons between conditions are made within
strata. If the strata are homogeneous, the between-cluster variance relevant
to estimating the treatment effect is reduced. Thus matching and stratifica-
tion can increase power and reduce sample size requirements, in addition to
promoting balance on baseline covariates. However, this variance reduction
comes with a loss of df for estimating the treatment effect.
1.4.2 Dichotomous outcomes
In this section, sample size and power formulas for cluster randomized tri-
als with dichotomous outcomes are derived using logic similar to that for
CRTs with continuous outcomes. In the section on analysis, we discussed
two hierarchical models for binary data, the cluster-level proportions model
and the cluster-level log odds model. For sample size and power, we focus
on the cluster-level proportions model, which has parameters that are easier
to understand. Since many concepts were previously discussed for continuous
outcomes, our discussion of dichotomous outcomes is more brief.
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1.4.2.1 Sample size and power
Using the cluster-level proportions model, the intervention effect can be esti-
mated as the difference in sample proportions, pˆi1 − pˆi2, and its variance, also
given in (1.16), is
V ar(pˆi1 − pˆi2) =
[
pi1(1− pi1)
n1n2/2
+
pi2(1− pi2)
n1n2/2
]
[1 + (n1 − 1)ρd] . (1.47)
where ρd is as defined in (1.14). For large samples, the test statistic (pˆi1 −
pˆi2)/
√
V ar(pˆi1 − pˆi2) has a standard normal distribution under the null hy-
pothesis. Using this approach, the total number of clusters required to achieve
power of 1− β with two-sided α of 0.05 when cluster size is n1 is
n2 ≥
2(z1−α/2 + z1−β)2[pi1(1− pi1) + pi2(1− pi2)][1 + (n1 − 1)ρd]
n1(pi1 − pi2)2 , (1.48)
This formula assumes equal allocation, constant cluster sizes and equal ICCs
in each arm. These assumptions are relaxed in later sections. This formula can
also be derived by calculating the total sample size requirement across both
arms, N , for independent observations,
N =
2(z1−α/2 + z1−β)2[pi1(1− pi1) + pi2(1− pi2)]
(pi1 − pi2)2 , (1.49)
and inflating by the design effect. Some authors recommend adding one extra
cluster per treatment arm [23]. Power for a given cluster size and number of
clusters can be obtained by solving the equation for z1−β and applying the
standard normal cumulative distribution function. R functions for sample size
and power computation are given below.
sampsize.crt.bal.bin <- function(p1, p2, rho, n1, beta, alpha){
za <- qnorm(1-alpha/2)
zb <- qnorm(1-beta)
num <- 2*(za+zb)^2*(p1*(1-p1)+p2*(1-p2))*(1+(n1-1)*rho)
denom <- n1*(p1-p2)^2
n2 <- num/denom
print("Total number of clusters required is")
print(n2)
print("Required clusters per arm is")
print(ceiling(n2/2))
}
power.crt.bal.bin <- function(p1, p2, rho, n1, n2, alpha){
za <- qnorm(1-alpha/2)
num <- n1*n2*(p1-p2)^2
denom <- 2*(p1*(1-p1)+p2*(1-p2))*(1+(n1-1)*rho)
zb <- sqrt(num/denom) - za
pnorm(zb)
}
Cluster Randomized Trials 33
Example. Suppose that we anticipate proportions of 0.3 and 0.5 in the two
arms and clusters each have 25 members. The ICC is estimated to be 0.03.
Using the command
sampsize.crt.bal.bin(.3, .5, .03, 25, 0.2, 0.05)
the trial is estimated to need 7 clusters per condition to achieve at least 80%
power with two-sided α of 0.05. The actual power can be computed using the
command
power.crt.bal.bin(.3, .5, .03, 25, 14, 0.05)
which indicates that the actual power is 84.5%.
1.4.2.2 Sample size per cluster
Given a fixed total number of clusters n2, the required cluster size is
n1 =
(1− ρd)[pi1(1− pi1) + pi2(1− pi2)](z1−α/2 + z1−β)2
(pi1 − pi2)2n2/2− ρd[pi1(1− pi1) + pi2(1− pi2)] . (1.50)
As mentioned for continuous outcomes, it will not always be possible to achieve
desired power with a fixed number of clusters, even if the sample size per
cluster is extremely large.
1.4.2.3 Unequal ICCs in treatment arms
In some cases we may wish to use separate ICC estimates in the two arms.
For example, we may anticipate more dispersion of cluster-level proportions
in the intervention arm, or we may want to account for the fact that the
ICC depends on the underlying proportion as V ar(pˆ)/[pi(1 − pi)]; see (1.14).
Separate ICCs by arm can be incorporated into the sample size formula to
yield
n2 ≥
2(z1−α/2 + z1−β)2[pi1(1− pi1)Deff1] + pi2(1− pi2)Deff2]
n1(pi1 − pi2)2 , (1.51)
where Deffk = 1 + (n1 − 1)ρdk is the design effect in arm k.
1.4.2.4 Unequal allocation
If the number of clusters allocated to arms 1 and 2 are rn2 and (1 − r)n2,
respectively, the variance of the risk difference becomes
V ar(pˆi1 − pˆi2) = pi1(1− pi1)d1
rn1n2
+
pi2(1− pi2)d2
(1− r)n1n2 (1.52)
where the dk are the design effects, dk = 1 + (n1 − 1)ρk, k = 1, 2; we have
allowed unequal ICCs and thus unequal design effects for generality. As dis-
cussed for continuous outcomes, the optimal allocation that minimizes the
variance of the treatment effect estimator is
√
d1/(
√
d1 +
√
d2).
34 Textbook of Clinical Trials in Oncology
1.4.2.5 Covariates
The impact of cluster-level and individual-level covariates on the power of
CRTs with continuous outcomes was discussed in Section 1.4.1.6. The impact
of adjusting for covariates in trials with binary outcomes is more complex.
Due to the nonlinearity of the logistic regression model, it is difficult to derive
tractable expressions for the variances in adjusted models [55]. Furthermore,
in a logistic regression model, the unadjusted and adjusted treatment effect
parameters differ. Unadjusted analyses yield marginal estimates that compare
an intervention subject with a randomly selected control subject. Adjusted
analyses yield conditional estimates that compare an intervention subject to
a control subject with the same covariate values. For continuous outcomes,
the adjusted and unadjusted treatment effects are the same, but this is not
generally true for binary outcomes [22]. In a logistic model, the adjustment
typically increases the estimated treatment effect; that is, estimated odds
ratios will be further from 1 (where an odds ratio of 1 indicates no treatment
effect). Furthermore, including covariates in a logit model tends to increase
the variance of the estimated treatment effect in log odds terms [52].
For these reasons, simple formulas that account for the impact of covariates
on power in a CRT with a binary outcome analyzed using a mixed effects logit
model are lacking. However, Schochet [55] provides an approach that is based
on using a GEE estimator rather than the mixed effects logit model. A key
finding is that gains in power due to covariate adjustment are likely to be
smaller for binary outcomes than they are for continuous outcomes.
1.4.2.6 Varying cluster sizes
Varying cluster sizes are less efficient for estimating treatment effects than are
equal cluster sizes, as previously discussed. The same approach for accounting
for this reduction in efficiency can be used for both continuous and binary
outcomes; see Section 1.4.1.7 for more details.
1.5 Additional resources
Books on the design and analysis of cluster randomized trials include Mur-
ray [43], Donner and Klar [15], Eldridge and Kerry [17], Campbell and Wal-
ters [8] and Hayes and Moulton [23]. Some of these books, e.g. [23], discuss
time-to-event outcomes, rates and counts. Survival outcomes are also dis-
cussed in [31]. Power analysis for trials with multilevel data, including clus-
ter randomized trials, multicenter trials and individually randomized group
treatment trials, is discussed in Moerbeek and Teerenstra [41]. Sample size
calculation for clustered and longitudinal outcomes are discussed in Ahn et
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al. [1]. Some recent reviews summarize key results for sample size calculations
for CRTs [18, 53].
Many journals require that reports of trials conform to the guidelines in the
Consolidated Standards of Reporting Trials (CONSORT) statement. There is
a CONSORT statement extension specifically for cluster randomized trials [9]
that provides a checklist of items to include in the trial report, including the
ICC, which researchers often neglect to report [13].
1.5.1 Resources for other designs
This chapter has covered outcome analysis and sample size and power for
some common designs of cluster randomized trials. We discuss several major
designs and provide references.
Individually randomized group treatment trials. In an individu-
ally randomized group treatment trial, individuals are randomized to study
conditions but receive their intervention with other participants, typically in
a group setting, or through a change agent shared with other participants.
For example, in a mindful awareness intervention for breast cancer survivors,
participants randomized to the intervention were assigned to groups who at-
tended classes together [7]. In these studies, there is little or no group-level
ICC at baseline, but a positive ICC is expected among the outcomes of indi-
viduals within the same group. Special methods are needed for analysis and
sample size estimation for these studies. Literature discussing these studies
includes [4, 46, 45, 41, 51].
Cluster-randomized crossover trials. In a simple crossover trial, each
subject receives each treatment in random order. Because each subject serves
as his or her own control, a crossover design can be quite powerful. In a cluster
randomized crossover trial, clusters are randomly allocated to a sequence of
interventions. Two designs can be distinguished: crossover at the cluster level,
in which each subject is included in only one of the treatment periods, and
crossover at the subject level, in which each subject is observed in both peri-
ods [50]. Crossover CRTs are discussed in [20, 50, 49], and a brief summary
of sample size formulas is provided in [12].
Stepped wedge trials. A stepped wedge trial is similar to a crossover trial
except that the crossovers are all in one direction, from control to intervention
condition, and are staggered over time. Clusters are randomized to cross over
to the intervention at time points called steps, and all clusters end the trial
in the intervention condition. References for stepped wedge trials include [3,
24, 25, 64].
1.5.2 Resources for power and sample size calculation
The National Institutes of Health has a website with guidance on research
methods related to studies that randomize groups or clusters or that deliver in-
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terventions to groups at https://researchmethodsresources.nih.gov. The web-
site includes a sample size calculator.
The free software program Optimal Design Plus Empirical Evidence in-
cludes power and sample size calculation for more complex design elements
such as three or four levels. The program and documentation are available at
http://www.wtgrantfoundation.org.
Moerbeek and Teerenstra [41] describe the SPA-ML (Statistical Power
Analysis for Multi-Level designs) program, which is available for free download
at http://tinyurl.com/SPAML. Their book describes the use of the program,
which currently only handles continuous outcomes.
Campbell and Walters [8] discuss both data analysis and power and sample
size for CRTs, and provide code in R, Stata and SPSS. The code is available
at their website http://sheffield.ac.uk/scharr/sections/dts/statistics.
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